MedKoo Cat#: 527771 | Name: Naltriben mesylate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Naltriben is a highly selective δ2 opioid receptor antagonist.Naltriben (NTB) has been used to differentiate the subtypes of delta opioid receptors, delta1 and delta2. NTB displaced the specific binding of [3H]DAMGO with Ki value of 19.79 +/- 1.12 nM in rat cortex membranes. Specific binding of [3H]diprenorphine ([3H]DIP) was inhibited by NTB with Ki value of 82.75 +/- 6.32 nM in the presence of DAMGO and DPDPE. Naltriben enhanced the MAPK/ERK signaling pathway, but not the PI3k/Akt pathway. Therefore, potentiated TRPM7 activity contributes to the devastating migratory and invasive characteristics of GBM.

Chemical Structure

Naltriben mesylate
Naltriben mesylate
CAS#122517-78-6 (mesylate)

Theoretical Analysis

MedKoo Cat#: 527771

Name: Naltriben mesylate

CAS#: 122517-78-6 (mesylate)

Chemical Formula: C27H29NO7S

Exact Mass: 415.1784

Molecular Weight: 511.59

Elemental Analysis: C, 63.39; H, 5.71; N, 2.74; O, 21.89; S, 6.27

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
10mg USD 750.00 2 Weeks
25mg USD 1,350.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
111555-58-9 (free base) 122517-78-6 (mesylate)
Synonym
Naltriben mesylate; Naltrindole benzofuran; NIH 10924; NIH-10924; NIH10924;
IUPAC/Chemical Name
4,8-Methano-8aH-bisbenzofuro[3,2-e:2',3'-g]isoquinoline-1,8a-diol, 7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-, (4bS,8R,8aS,14bR)-, methanesulfonic acid
InChi Key
XRRFZOCDAWPIBB-IDRHMUJXSA-N
InChi Code
InChI=1S/C26H25NO4.CH4O3S/c28-18-8-7-15-11-20-26(29)12-17-16-3-1-2-4-19(16)30-22(17)24-25(26,21(15)23(18)31-24)9-10-27(20)13-14-5-6-14;1-5(2,3)4/h1-4,7-8,14,20,24,28-29H,5-6,9-13H2;1H3,(H,2,3,4)/t20-,24+,25+,26-;/m1./s1
SMILES Code
OC1=C2C([C@]34CCN(CC5CC5)[C@@]6([H])[C@]3(O)CC7=C(OC8=CC=CC=C87)[C@]4([H])O2)=C(C6)C=C1.CS(=O)(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Naltriben is a highly selective δ2 opioid receptor antagonist.
In vitro activity:
First, using the whole-cell patch-clamp technique, this study showed that naltriben enhanced the endogenous TRPM7-like current in U87 cells. In addition, with Fura-2 Ca2+ imaging, we observed robust Ca2+ influx following naltriben application. Naltriben significantly enhanced U87 cell migration and invasion (assessed with scratch wound assays, Matrigel invasion experiments, and MMP-2 protein expression), but not viability and proliferation (evaluated with MTT assays). Reference: Oncotarget. 2017 Feb 14;8(7):11239-11248. https://pubmed.ncbi.nlm.nih.gov/28061441/
In vivo activity:
The objective of the present study was to examine the effects of the delta 2 receptor antagonist naltriben (0.60-4.0 mg/kg) on operant responding maintained by the presentation of ethanol (EtOH) or saccharin in alcohol-preferring (P) rats. Naltriben (0.9-4.0 mg/kg) reduced EtOH-maintained responding by 44-76%, while saccharin-maintained responding was reduced only by the highest dose of naltriben (4.0 mg/kg). A Reference: Psychopharmacology (Berl). 1999 Nov;147(1):81-9. https://pubmed.ncbi.nlm.nih.gov/10591872/

Preparing Stock Solutions

The following data is based on the product molecular weight 511.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Wong R, Turlova E, Feng ZP, Rutka JT, Sun HS. Activation of TRPM7 by naltriben enhances migration and invasion of glioblastoma cells. Oncotarget. 2017 Feb 14;8(7):11239-11248. doi: 10.18632/oncotarget.14496. PMID: 28061441; PMCID: PMC5355261. 2. June HL, McCane SR, Zink RW, Portoghese PS, Li TK, Froehlich JC. The delta 2-opioid receptor antagonist naltriben reduces motivated responding for ethanol. Psychopharmacology (Berl). 1999 Nov;147(1):81-9. doi: 10.1007/s002130051145. PMID: 10591872. 3. Krishnan-Sarin S, Portoghese PS, Li TK, Froehlich JC. The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol Biochem Behav. 1995 Sep;52(1):153-9. doi: 10.1016/0091-3057(95)00080-g. PMID: 7501658.
In vitro protocol:
1. Wong R, Turlova E, Feng ZP, Rutka JT, Sun HS. Activation of TRPM7 by naltriben enhances migration and invasion of glioblastoma cells. Oncotarget. 2017 Feb 14;8(7):11239-11248. doi: 10.18632/oncotarget.14496. PMID: 28061441; PMCID: PMC5355261.
In vivo protocol:
1. June HL, McCane SR, Zink RW, Portoghese PS, Li TK, Froehlich JC. The delta 2-opioid receptor antagonist naltriben reduces motivated responding for ethanol. Psychopharmacology (Berl). 1999 Nov;147(1):81-9. doi: 10.1007/s002130051145. PMID: 10591872. 2. Krishnan-Sarin S, Portoghese PS, Li TK, Froehlich JC. The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol Biochem Behav. 1995 Sep;52(1):153-9. doi: 10.1016/0091-3057(95)00080-g. PMID: 7501658.
1: Maslov LN, Oeltgen PR, Lishmanov YB, Brown SA, Barzakh EI, Krylatov AV, Pei JM. Activation of peripheral delta opioid receptors increases cardiac tolerance to arrhythmogenic effect of ischemia/reperfusion. Acad Emerg Med. 2014 Jan;21(1):31-9. doi: 10.1111/acem.12286. PubMed PMID: 24552522. 2: Milan-Lobo L, Whistler JL. Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking. J Pharmacol Exp Ther. 2011 Jun;337(3):868-75. doi: 10.1124/jpet.111.179093. Epub 2011 Mar 21. PubMed PMID: 21422164; PubMed Central PMCID: PMC3097170. 3: Zhu M, Cho YK, Li CS. Activation of delta-opioid receptors reduces excitatory input to putative gustatory cells within the nucleus of the solitary tract. J Neurophysiol. 2009 Jan;101(1):258-68. doi: 10.1152/jn.90648.2008. Epub 2008 Nov 19. PubMed PMID: 19019978; PubMed Central PMCID: PMC2637018. 4: Joly N, El Aneed A, Martin P, Cecchelli R, Banoub J. Structural determination of the novel fragmentation routes of morphine opiate receptor antagonists using electrospray ionization quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(21):3119-30. Erratum in: Rapid Commun Mass Spectrom. 2006;20(16):2519. PubMed PMID: 16200660. 5: Lever JR, Scheffel U. Selective in vivo binding of [3H]naltriben to delta-opioid receptors in mouse brain. Eur J Pharmacol. 1998 Jun 5;350(2-3):335-44. PubMed PMID: 9696425.